A reduced dose of apixaban may be considered when treating VTE in patients with severe or end-stage renal disease.
Background: As preferences for oral anticoagulation shift from warfarin to direct oral anticoagulants (DOACs), a new care management model is needed. A population approach leveraging…
Background: As preferences for oral anticoagulation shift from warfarin to direct oral anticoagulants (DOACs), a new care management model is needed. A population approach leveraging…
Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of…
This quality improvement intervention was associated with an acceleration of a preexisting decrease in aspirin use among patients taking warfarin for atrial fibrillation and/or venous…
ACC Emerging Faculty Leadership Academy Call for Nominations – Due January 2, 2024 The American College of Cardiology (ACC) is now accepting nominations for the…
Twenty years ago, beloved NBC journalist David Bloom passed away from a pulmonary embolism while embedded with American troops in Iraq. His widow Melanie joins…
Join us for an inspiring and heartfelt interview with Melanie Bloom, the beloved wife of the late global news correspondent, David Bloom. In this exclusive…
Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences,
